Search results for "prostate"
showing 10 items of 621 documents
Inverse Comorbidity: The Power of Paradox in the Advancement of Science
2013
Abstract: Research on comorbidity and multimorbidity is finally receiving the attention it deserves, particularly considering the magnitude and impact they have on health and the delivery of healthcare [1,2]. Numerous studies have demonstrated that individuals with Down’s syndrome, Parkinson’s disease, schizophrenia, diabetes, anorexia nervosa, Alzheimer’s disease, allergy related diseases, multiple sclerosis or Huntington’s disease (among other health problems) are protected against many forms of cancer, including solid tumors, smoking-related tumors and prostate cancer. This apparent anti-cancer effect, which we have termed inverse cancer comorbidity, has been obse…
Clinical and biochemical markers of visceral adipose tissue activity: Body mass index, visceral adiposity index, leptin, adiponectin, and matrix meta…
2018
Context: The correlation between aggressive prostate cancer and obesity mainly based on body mass index (BMI) and pathology after surgery remains controversial. Aims: The aim of the study was to correlate BMI, visceral adiposity index (VAI), and the plasmatic levels of leptin, adiponectin, and matrix metalloproteinase-3 (MMP-3), and biomarkers of adipose tissue function, with the detection of Gleason patterns 4 and 5 at biopsy. Subjects and Methods: Consecutive patients with prostate cancer at 12-core transrectal biopsy were enrolled. BMI, waist circumference (WC), blood samples to evaluate the plasmatic levels of triglycerides (TG) and high-density lipoproteins (HDL), adiponectin, leptin, …
Clinical implications ofCYP3Apolymorphisms
2006
Due to their enormous substrate spectrum CYP3A4, -3A5 and -3A7 constitute the most important drug-metabolising enzyme subfamily in humans. CYP3As are expressed predominantly, but not exclusively, in the liver and intestine, where they participate in the metabolism of 45 - 60% of currently used drugs and many other compounds such as steroids and carcinogens. CYP3A expression and activity vary interindividually due to a combination of genetic and nongenetic factors such as hormone and health status, and the impact of environmental stimuli. Over the past several years, genetic determinants have been identified for much of the variable expression of CYP3A5 and -3A7, but not for CYP3A4. Using th…
Prostatectomia radicale mini laparoscopica: note di tecnica e risultati comparativi
2014
Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.
2004
Today, androgen deprivation therapy is a cornerstone of treatment for advanced prostate cancer, although it presents important complications such as osteoporosis. Neridronate, a relatively new bisphosphonate, is able to prevent bone loss in patients with prostate cancer during androgen ablation. Introduction: Androgen-deprivation therapy (ADT) is a cornerstone of treatment for advanced prostate cancer. This therapy has iatrogenic complications, such as osteoporosis. The aim of our study was to evaluate the efficacy of neridronate, a relatively new bisphosphonate, to prevent bone loss during androgen ablation. Materials and Methods: Forty-eight osteoporotic patients with prostate cancer, tre…
Wpływ stanu napięcia mięśni dna miednicy na ocenę poziomu zaburzeń erekcji i nietrzymania moczu u osób po prostatektomii radykalnej. Doniesienie wstę…
2017
Celem pracy była ocena, jak napięcie mięśni dna miednicy (MDM) mierzonego za pomocą sEMG wpływa na ocenę obiektywną i subiektywną trzymania moczu oraz zaburzeń erekcji. W badaniach uczestniczyło 10 mężczyzn, będących po zabiegu prostatektomii. Nasilenie objawów nietrzymania moczu oceniano na podstawie kwestionariusza ICIQ-SF, aktywność seksualną kwestionariuszem IIEF-5. Nie wykazano istotnego statystycznie związku między napięciem MDM, ocenianego za pomocą sEMG, a obiektywnymi wyznacznikami nietrzymania moczu, jednakże zaobserwowano tendencję, że niższe napięcie MDM występuje częściej u chorych ze wszystkimi dolegliwościami w ocenie subiektywnej.
IS VISCERAL ADIPOSITY INDEX (VAI)RELATED TO PROSTATE CANCER DETECTED BY BIOPSY?
2014
association between obesity and prostate cancer, yielding inconsistent results. Metabolic syndrome has been suggested to promote aggressive prostate tumors. In a previous study we failed to detect a relation between Body Mass Index (BMI) and prostate cancer Gleason score (1). BMI, although routinely adopted to measure obesity, has low sensitivity and specificity. A novel sex-specific obesity index, based on waist circumference (WC), BMI, triglycerides (TGs) and high density lipoproteins (HDL), the Visceral Adiposity Index (VAI), has been proposed to estimate the visceral adiposity dysfunction (2). The aim of our preliminary research was to correlate VAI and BMI with the presence of prostate…
DES-polyacetals as polymer therapeutics for the treatment of prostate cancer
2012
Esta tesis se centra en el diseño de nuevos conjugados polímero-fármaco sensibles a pH para usarse como agentes únicos o en terapia de combinación para el tratamiento del cáncer hormono-dependiente, en particular cáncer de próstata. Éstos conjugados se basan en sístemas poliacetalicos previamente descritos en los que el fármaco forma parte de la cadena principal del polímero. En el microambiente tumoral o después de la absorción celular por endocitosis, el descenso del pH encontrado en el compartimiento ácido del endosoma lisosomal, desencadena la degradación del polímero y como consecuencia la liberación del fármaco que se difunde fuera en el citosol. Para el diseño de éstos sistemas, la n…